Macrocyclic derivatives for the treatment of diseases

A compound of formula (V)

• wherein:
• A is a ring selected from C6-C12 aryl and 5-6 membered heteroaryl;
• R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl, wherein each hydrogen on said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —CN, —OR9, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 or —C(O)NR9R10;
• each R2 is independently selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, 5-6 membered heteroaryl, —S(O)tR7, —S(O)2NR7R8, —S(O)2OR7, —NO2, —(CR5R6)qNR7R8, —N(CR5R6)(CR5R6)qNR7R8, —OR7, —O(CR5R6)(CR5R6)qOR7, —O(CR5R6)(CR5R6)qR7, —CN, —C(O)R7, —OC(O)R7, —O(CR5R6)qR7, —NR7C(O)R8, —(CR5R6)qC(O)OR7, —(CR5R6)qNR7R8, —C(═NR7)NR7R8, —NR7C(O)NR7R8, —NR7S(O)2R8 and —(CR5R6)qC(O)NR7R8;
• wherein each hydrogen on said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —OR9, —CN, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 or —C(O)NR9R10;
• R3 and R4 are each independently selected from hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each hydrogen on C1-C6 alkyl and C3-C6 cycloalkyl may be independently optionally substituted by halogen, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —CN, —OR9, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 or —C(O)NR9R10;
• each R5 and R6 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, 5-6 membered heteroaryl, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —CN, —OR9, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 and —C(O)NR9R10;
• wherein each hydrogen on said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —CN, —OR9, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 or —C(O)NR9R10;
• each R7 and R8 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl, wherein each hydrogen on said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH2, —S(O)tR9, —S(O)2NR9R10, —S(O)2OR9, —NO2, —OR9, —CN, —C(O)R9, —OC(O)R9, —NR9C(O)R10, —C(O)OR9, —C(═NR9)NR9R10, —NR9C(O)NR9R10, —NR9S(O)2R10 or —C(O)NR9R10;
• each R9 and R10 is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl;
• p is 0, 1, 2, 3 or 4;
• each q is independently 0, 1, 2 or 3;
• and
• each t is independently 0, 1 or 2;
• or a pharmaceutically acceptable salt thereof.